Antibacterial composition and uses thereof
Inventors
FEVRE, CINDY • BLOIS, Hélène • Medina, Mathieu
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12280080-B2
Publication Date
2025-04-22
Expiration Date
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Staphylococcus aureus strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy and as companion diagnostic.
Core Innovation
The invention relates to an antibacterial composition and related preparation for treating or addressing Staphylococcus aureus using lytic bacteriophages. The system includes bacteriophages having lytic activity against S. aureus strains, and the bacteriophages are selected based on genome nucleotide sequence criteria tied to SEQ ID NOs: 1 to 4 or sequences having at least 95% identity thereto. The disclosed bacteriophages include PN1137, PN1493, PN1815, and PN1957, and the composition includes a pharmaceutically acceptable excipient or carrier.
The disclosed phage-therapy antibacterial system is defined by genomes matching SEQ ID NOs: 1 to 4, and it specifies taxonomy consistent with Caudovirales, including Podoviridae and Myoviridae. The document describes characterization across a panel of 109 S. aureus strains, including assessment of host range spectrum and total lytic activity, where at least one phage achieves total lysis for at least one strain and the activity is described as meeting or exceeding specified activity thresholds for a plurality of strains. It also describes exemplar phage cocktail pairings with complementary spectra, including cocktail compositions such as PN1493+PN1957 and PN1815+PN1957.
The invention further encompasses a method for preparing the antibacterial composition by producing at least one lytic bacteriophage selected by genome nucleotide sequence criteria (SEQ ID NOs: 1 to 4 or identity thresholds) and combining the bacteriophage with a pharmaceutically suitable carrier or excipient. The document additionally includes companion diagnostic concepts based on measuring lytic activity or sensitivity to select effective phage cocktails, and it includes in vivo mouse efficacy model outlines for foot ulcer infections and bone and joint or prosthetic joint infections, including both diabetic and non-diabetic contexts.
Claims Coverage
The document includes two independent claims: an antibacterial composition claim and a method for preparing that composition. Across these independent claims, the core inventive features center on selecting lytic bacteriophages against S. aureus based on genome sequence criteria tied to SEQ ID NOs: 1 to 4 (or high-identity variants), and formulating with a pharmaceutically acceptable excipient/carrier that includes a preservative to preserve bacteriophage activity, or combining with a pharmaceutically suitable carrier/excipient.
Sequence-defined lytic bacteriophages for S. aureus
An antibacterial composition comprising at least one bacteriophage having lytic activity against at least one Staphylococcus aureus strain, the bacteriophage being selected from the bacteriophages having a genome comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 4 or a sequence having at least 95% identity thereto.
Preservative-containing pharmaceutically acceptable excipient or carrier
The antibacterial composition of claim 1 wherein the pharmaceutically acceptable excipient or carrier comprises a preservative in an amount effective to preserve the activity of the bacteriophage.
Producing and combining sequence-defined lytic bacteriophages
A method for preparing an antibacterial composition comprising producing at least one bacteriophage having lytic activity against at least one Staphylococcus aureus strain, the bacteriophage being selected from the bacteriophages having a genome comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 4 or a sequence having at least 95% identity thereto, and combining the bacteriophage with a pharmaceutically suitable carrier or excipient.
Overall, the independent claims are grounded in sequence-defined selection of lytic bacteriophages against S. aureus (SEQ ID NOs: 1 to 4 or ≥95% identity) and in formulation or combination with pharmaceutically suitable excipients, with the composition claim additionally requiring a preservative effective to preserve bacteriophage activity.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?